» Articles » PMID: 26510990

Longitudinal Immune Profiles in Type 1 Leprosy Reactions in Bangladesh, Brazil, Ethiopia and Nepal

Abstract

Background: Acute inflammatory reactions are a frequently occurring, tissue destructing phenomenon in infectious- as well as autoimmune diseases, providing clinical challenges for early diagnosis. In leprosy, an infectious disease initiated by Mycobacterium leprae (M. leprae), these reactions represent the major cause of permanent neuropathy. However, laboratory tests for early diagnosis of reactional episodes which would significantly contribute to prevention of tissue damage are not yet available. Although classical diagnostics involve a variety of tests, current research utilizes limited approaches for biomarker identification. In this study, we therefore studied leprosy as a model to identify biomarkers specific for inflammatory reactional episodes.

Methods: To identify host biomarker profiles associated with early onset of type 1 leprosy reactions, prospective cohorts including leprosy patients with and without reactions were recruited in Bangladesh, Brazil, Ethiopia and Nepal. The presence of multiple cyto-/chemokines induced by M. leprae antigen stimulation of peripheral blood mononuclear cells as well as the levels of antibodies directed against M. leprae-specific antigens in sera, were measured longitudinally in patients.

Results: At all sites, longitudinal analyses showed that IFN-γ-, IP-10-, IL-17- and VEGF-production by M. leprae (antigen)-stimulated PBMC peaked at diagnosis of type 1 reactions, compared to when reactions were absent. In contrast, IL-10 production decreased during type 1 reaction while increasing after treatment. Thus, ratios of these pro-inflammatory cytokines versus IL-10 provide useful tools for early diagnosing type 1 reactions and evaluating treatment. Of further importance for rapid diagnosis, circulating IP-10 in sera were significantly increased during type 1 reactions. On the other hand, humoral immunity, characterized by M. leprae-specific antibody detection, did not identify onset of type 1 reactions, but allowed treatment monitoring instead.

Conclusions: This study identifies immune-profiles as promising host biomarkers for detecting intra-individual changes during acute inflammation in leprosy, also providing an approach for other chronic (infectious) diseases to help early diagnose these episodes and contribute to timely treatment and prevention of tissue damage.

Citing Articles

Rapid test for Mycobacterium leprae infection: a practical tool for leprosy.

Pierneef L, van Hooij A, de Jong D, Wassenaar G, Verhard E, Tjon Kon Fat E Infect Dis Poverty. 2024; 13(1):88.

PMID: 39617937 PMC: 11610287. DOI: 10.1186/s40249-024-01262-9.


Leprosy.

Grijsen M, Nguyen T, Pinheiro R, Singh P, Lambert S, Walker S Nat Rev Dis Primers. 2024; 10(1):90.

PMID: 39609422 DOI: 10.1038/s41572-024-00575-1.


Metformin as adjunctive therapy in combination with multidrug treatment for multibacillary leprosy: A protocol for a randomized double-blind, controlled Phase 2 trial in Indonesia (MetLep Trial).

Krismawati H, Muchtar S, Rahardjani M, Utami N, Oktaviani M, Puspatriani K Wellcome Open Res. 2024; 8():289.

PMID: 38808319 PMC: 11131563. DOI: 10.12688/wellcomeopenres.19455.2.


The role of CXCL10 as a biomarker for immunological response among patients with leprosy: a systematic literature review.

Prakoeswa F, Haningtyas N, Dewi L, Handoko E, Azenta M, Ilyas M PeerJ. 2024; 12:e17170.

PMID: 38590701 PMC: 11000641. DOI: 10.7717/peerj.17170.


Leprosy: treatment, prevention, immune response and gene function.

Li X, Ma Y, Li G, Jin G, Xu L, Li Y Front Immunol. 2024; 15:1298749.

PMID: 38440733 PMC: 10909994. DOI: 10.3389/fimmu.2024.1298749.


References
1.
Montoya D, Cruz D, Teles R, Lee D, Ochoa M, Krutzik S . Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe. 2009; 6(4):343-53. PMC: 2764558. DOI: 10.1016/j.chom.2009.09.002. View

2.
Moraes M, Pacheco A, Schonkeren J, Vanderborght P, Nery J, Santos A . Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes Immun. 2004; 5(7):592-5. DOI: 10.1038/sj.gene.6364122. View

3.
Martins M, Guimaraes M, Spencer J, Hacker M, Costa L, Carvalho F . Pathogen-specific epitopes as epidemiological tools for defining the magnitude of Mycobacterium leprae transmission in areas endemic for leprosy. PLoS Negl Trop Dis. 2012; 6(4):e1616. PMC: 3335884. DOI: 10.1371/journal.pntd.0001616. View

4.
Gupta U, Katoch K, Singh H, Natrajan M, Katoch V . Persister studies in leprosy patients after multi-drug treatment. Int J Lepr Other Mycobact Dis. 2006; 73(2):100-4. View

5.
Manandhar R, Shrestha N, Butlin C, Roche P . High levels of inflammatory cytokines are associated with poor clinical response to steroid treatment and recurrent episodes of type 1 reactions in leprosy. Clin Exp Immunol. 2002; 128(2):333-8. PMC: 1906406. DOI: 10.1046/j.1365-2249.2002.01791.x. View